Alveolar type 2 (AT2) cell endoplasmic reticulum (ER) stress is a prominent feature in adult and pediatric interstitial lung disease (ILD and ChILD), but in vivo models linking AT2 cell ER stress to ILD have been elusive. Based on a clinical ChILD case we identified a critical cysteine residue in the Surfactant Protein C gene (SFTPC) BRICHOS domain whose mutation induced ER stress in vitro. To model this in vivo, we generated a knock-in model expressing a cysteine-to-glycine substitution at codon 121 (C121G) in the Sftpc gene. Sftpc C121G expression during fetal development resulted in a toxic gain of function resulting in fatal post-natal respiratory failure from disrupted lung morphogenesis. Induced Sftpc C121G expression in adult mice resulted in an ER retained pro-protein causing AT2 cell ER stress. Sftpc C121G AT2 cells were a source of cytokines expressed in concert with development of a polycellular alveolitis. These cytokines were subsequently found in a high-dimensional proteomic screen of bronchoalveolar lavage fluid from ChILD patients with the same class of SFTPC mutations. Following alveolitis resolution, Sftpc C121G mice developed spontaneous pulmonary fibrosis and restrictive lung impairment. This model provides proof of concept linking AT2 cell ER stress to fibrotic lung disease coupled with translationally relevant biomarkers.
INTRODUCTION
Adult Interstitial lung disease (ILD) and pediatric childhood ILD (ChILD) are defined pathologically by interstitial fibrosis, inflammation, or the combination of fibrosis and inflammation (1, 2) .
With thickening of the alveolar interstitum causing impairment in effective gas exchange, the clinical course is often progression to chronic respiratory failure (3, 4) . Over the past decade, the alveolar type 2 (AT2) cell has come to the forefront as a key driver of lung fibrosis and ILD (5, 6) . The focus on the AT2 cell is in part due to the identification of disease causing mutations in the AT2 cell restricted Surfactant Protein C gene (SFTPC) in both pediatric patients with ChILD and in a subset of adult patients with familial ILD (7) (8) (9) ). The recent demonstration by our group of the occurrence of spontaneous lung fibrosis with in vivo expression of the Sftpc I73T trafficking mutation in a preclinical mouse mode has provided further proof of concept for the AT2 cell as a proximal driver of ILD (10) . While the SFTPC I73T mutation, which causes a block in AT2 cell macroautophagy, is the most common clinical SFTPC mutation identified, a majority of the 60 described mutations in the SFTPC gene associated with human disease occur in the distal C-terminal (residues 94-197) "BRICHOS" domain of the Surfactant Protein C (SP-C) pro-protein (proSP-C). Their expression results in pro-protein aggregation and induction of endoplasmic reticulum (ER) stress (11) (12) (13) (14) (15) (16) .
These cases further highlight the proximal position of the AT2 cell in the pathogenesis of pulmonary fibrosis and suggest AT2 cell ER stress may provide a broader mechanistic link between SFTPC BRICHOS mutation associated pediatric ChILD and adult ILD.
Markers of ER stress are also a prominent feature in the lung epithelium from patients with sporadic idiopathic pulmonary fibrosis (IPF), the most common adult ILD (17) ; however, the role of epithelial ER stress in disease pathogenesis is unclear. In vivo proof of concept studies linking SFTPC BRICHOS mutations, ER stress, and pulmonary fibrosis have been plagued by over and under expression of the mutant pro-protein isoforms, and have failed to establish a mechanistic connection. While the constitutive transgenic expression of a highly aggregation prone SFTPC mutation (SFTPC Exon4 ) resulted in disrupted lung morphogenesis with prenatal lethality (18) , inducible expression of a less severe mutation (SFTPC L188Q ) at lower levels produced an increased susceptibility to bleomycin fibrosis, but not spontaneous fibrotic remodeling (19) . This finding suggested that epithelial ER stress may not be a driver of fibrosis per se, but a marker of a dysfunctional and vulnerable epithelium, which requires a "second hit"
to cause disease.
Given the low level of SFTPC expression induced in the SFTPC L188Q mice, we sought to challenge this notion with the hypothesis that a more severe SFTPC BRICHOS mutation expressed at a more biologically relevant level would produce an ER stress based toxic gain of function resulting in a dysfunctional epithelial cell capable of driving a spontaneous lung phenotype. Based upon a pediatric case of ChILD with a mutation in the cysteine at codon 121 (C121), and previous ultrastructural analysis demonstrating that the disulfide bond formed between C121 and cysteine 189 of the BRICHOS domain mediates the primary folding of the proSP-C primary translation product (20) , we generated a murine model (Sftpc C121G ). Consistent with a misfolded isoform, the Sftpc C121G pro-protein is proximally retained in the ER and induces substantial epithelial ER stress both in vitro and in vivo. The resultant lung phenotype of AT2 cell driven spontaneous inflammation and subsequent fibrotic remodeling provides proof of concept linking SFTPC BRICHOS mutations and pulmonary fibrosis. The translational relevance of this model was further corroborated by a high-dimensional proteomic analysis of bronchoalveolar lavage fluid (BALF) from pediatric patients with SFTPC BRICHOS mutation-associated ChILD showing overlapping cytokine expression. The Sftpc C121G model, with relevant biomarker elaboration, thus establishes that AT2 cell ER stress is a sufficient driver for spontaneous lung inflammation and aberrant fibrotic lung remodeling.
RESULTS

In vitro expression of a clinical SFTPC cysteine 121 mutation induces ER stress by a proximally retained SP-C pro-protein
A male child of an uncomplicated pregnancy was born at 38 weeks gestation by spontaneous vaginal delivery to a 27 year-old mother. He subsequently developed respiratory failure in the first day of life requiring endotracheal intubation and mechanical ventilation. He received exogenous surfactant and was extubated and transitioned to nasal canula supplemental oxygen. In vitro modeling was performed to define the functional consequences of C121 mutations on proSP-C biosynthesis. Plasmids containing EGFP tagged wild-type SFTPC (EGFP/SP-C WT ) and two SFTPC mutants, EGFP/SP-C C121Y and EGFP/SP-C C121G , were transfected into HEK293 cell lines and interrogated for cellular expression patterns and post-translational processing. The SFTPC C121G mutation, which has also been described clinically (21) , was selected in addition to the clinical SFTPC C121Y mutation to generalize the importance of disulfide bonding in the pro-protein via the C121 thiol (20) . In contrast to the wild-type isoforms, western blot analysis of cell lysates showed a primary proSP-C translation product containing either cysteine mutant failed to undergo normal processing to a cleaved intermediate pro-protein in BiP (GRP78) protein in cells expressing either SFTPC mutation compared to wild-type SFTPC ( Figure   1E ). This was consistent with previously published in vitro studies of SFTPC BRICHOS mutants, which have demonstrated BiP to be a reliable marker of the ER stress response (13, 15) . These data collectively define a critical role of the C121 residue in the biosynthetic routing and processing of the proSP-C, and reveal an ER stress toxic gain of function with SFTPC C121 mutations.
Constitutive expression of the Sftpc C121G mutation in vivo phenocopies the human pediatric mutation
Given the importance of C121 in the processing of proSP-C in vitro, we utilized an ES cell recombineering strategy to selectively knock-in a homologous cysteine-to-glycine substitution at codon 121 (C121G) to the endogenous mouse Sftpc locus. Given that the functional consequences of each cysteine mutant isoform were equivalent in vitro, the C121G missense substitution was chosen for the in vivo knockin model to limit confounding variables related to residue side chain size, hydrophobicity, or potential posttranslational modification of a tyrosine residue. The resultant founder line (Sftpc C121Gneo/C121Gneo ) retained a PGK-Neomycin (PGK-neo) cassette in Intron 4 flanked by locus of X-over P1 (lox-P) sites (Supplemental Figure 1A) . Retention of the PGK-neo cassette rendered the Sftpc C121Gneo gene hypomorphic, a strategy employed for knock-in models of toxic gain of function mutations (10, 22, 23) , with mRNA levels in homozygous Sftpc C121Gneo animals limited to ~ 6% of that of littermates expressing two Sftpc WT alleles (Supplemental Figure 1B) . Despite AT2 cells lacking expression of proSP-C (Supplemental Figure 1C) and consistent with the phenotype of the Sftpc knockout mouse (24), the founder line was devoid of a spontaneous inflammatory or fibrotic phenotype when aged up to 52 weeks (Supplemental Figure 1D , E, F).
To evaluate the effect of increasing Sftpc C121G expression in the developing lung, we constitutively removed the Lox-P flanked PGK-neo cassette from Sftpc C121Gneo alleles by crossing the Sftpc
C121Gneo/C121Gneo
founder line to mice heterozygous for the CMV-Cre recombinase (a "deleter" line) (25) . The resultant progeny were either Sftpc WT/C121Gneo in mice not receiving the CMV-Cre allele, or heterozygous for the activated Sftpc C121G allele (Sftpc WT/C121G ), in mice receiving the CMV-Cre allele (Figure 2A ). Consistent with a dominant negative effect, heterozygous expression of Sftpc C121G caused abnormal processing of the wild-type SP-C pro-protein with reduced processing intermediates on western blotting for proSP-C ( Figure   2B ) and an 84.7% ± 3.2% (X ± SD, n=4) reduction in mature SP-C (mSP-C) protein in P2.5 lung homogenates ( Figure 2C ). This finding recapitulates data from SFTPC BRICHOS mutation patients whereby heterozygous expression of the SFTPC mutation dramatically blocks pro-protein processing, reducing the amount of mSP-C in patients' BALF (26) (27) (28) . Previous in vitro studies have shown mechanistically that heteromeric association between mutant and wild-type proSP-C proteins is responsible for the disruption of the intracellular trafficking of the wild-type proSP-C isoform (16, 29, 30) .
The constitutive Sftpc C121G expression model phenocopied many of the features of the pediatric disease (27, 31) . Similar to some cases of ChILD, including the one presented here (Figure 1) , a toxic gain of function was observed, with Sftpc WT/C121G mice developing a lethal post-natal respiratory failure with a median survival of 2.5 days ( Figure 2D) . Sftpc C121G expression manifested as respiratory distress and cyanosis between P1.5 and P3.5 ( Figure 2E) , with lung histology of distorted architecture; enlargement of airspaces, interstitial widening, inflammatory infiltrate, and proteinacious fluid in the airspaces ( Figure 2F) with features resembling the histology in the clinical SFTPC C121Y case ( Figure 1B) . Figure 3D ) (33, 34) . Expression of the Sftpc C121G mutation causes early morbidity and mortality from lung injury and AT2 cell driven polycellular alveolitis
Expression of mutant
Cre mice demonstrated tamoxifen dose dependent morbidity and mortality. At a dose of 350mg/kg tamoxifen the mice developed weight loss starting at 7 days post-tamoxifen with a nadir of 84.8% ± 9.6% (X ± SD, n=13) from baseline at 13 days ( Figure 5A ) in association with 40% early mortality ( Figure 5B ). Lower doses were non-fatal and a higher dose (600mg/kg) was 100% fatal (Supplemental Figure 4) . The weight loss and death were commensurate with hypoxemia ( Figure 5C ) and increased BALF total protein ( Figure 5D ). Histologically, the Sftpc C121G/C121G / R26 Cre mice developed acute, diffuse lung injury by day 14 ( Figure 5E ).
The parenchymal lung injury was accompanied by a polycellular alveolitis, with a substantial increase in total BALF cell counts beginning 7 days after tamoxifen and peaking at 2 weeks ( Figure 5F ).
BALF cytospins demonstrated a multiphasic inflammatory cell alveolitis with an early and sustained increase in macrophage/monocyte lineages beginning 7 days after tamoxifen, a rise in neutrophils starting 7 days after tamoxifen and peaking by 2 weeks, and an increase in eosinophils at 2 weeks ( Figure 5G and Supplemental Table 1 ). This pattern of granulocyte alveolitis mirrored that found in the Sftpc I73T model (10) . Total lymphocytes also increased by day 14 and were sustained through 28 days; however, at numbers one log-fold less than the macrophage/monocyte and granulocyte cell populations. weeks, but in the absence of weight loss or early mortality (Supplemental Figure 5 ).
To define the effector cell populations that precede the overt alveolitis, flow cytometry analysis of whole lung tissue was performed at 3 days post-tamoxifen using a gating strategy shown in Supplemental Figure 6 . By this algorithm, an early decrease in the relative percent of SigF + CD11b -resident alveolar macrophages was found ( Figure 5H ) commensurate with an influx of inflammatory CD11b + Ly6C hi monocytes ( Figure 5I ), a population recently implicated in fibrotic lung remodeling (39, 40) .
In order to define the potential mediators of effector cell recruitment, BALF samples at early and late stage alveolitis were analyzed by multiplex assay and ELISA (Supplemental Table 2 ). CCL2 (MCP1), CCL17 (TARC), and CCL7 (MCP-3) were found to be increased in the BALF of Sftpc C121G/C121G / R26
Cre mice compared to Sftpc WT / R26 Cre controls at the early time point ( Figure 6A ). Importantly, increases in AT2 cell mRNA expression of Ccl2, Ccl17, and Ccl7 occurred by 7 days suggesting a role for this cellular compartment as a source of these cytokines ( Figure 6B) . Notably, although elevations in cytokine levels for CCL2, CCL17 and CCL7 were not statistically significant at 3 days post-tamoxifen, there was a 2.6 ± 1.2 (X ± SD, n=4, p=0.01), 3.1 ± 1.0 (X ± SD, n=4, p=0.01), and a 3.0 ± 0.5 (X ± SD, n=4, p=0.005) fold increase in AT2 cell mRNA expression, respectively. These data coupled with the early influx of inflammatory monocytes suggest that local elaboration of these cytokines may contribute to the recruitment.
In addition to the monocyte/macrophage lineages, Sftpc C121G AT2 cells also contributed to granulocyte recruitment. Sftpc C121G AT2 cells had increased mRNA expression of Ccl11 and Il5 compared to control AT2 cells, and BALF showed an increase in the corresponding eosinophil chemokines CCL11
(Eotaxin) and IL5 at 1 week post-tamoxifen (Supplemental Figure 7) . This occurred in the absence of detectable increases in canonical Th2 cytokines IL4 and IL13. Additionally, a 10 fold increase in Sftpc C121G AT2 cell expression of the murine homolog to IL8 (neutrophil chemoattractant KC (Cxcl1/GroA)) occurred and was also reflected by elevated BALF KC/CXCL1 content at 1 week post-tamoxifen (Supplemental Figure 7 ). There was also a significant increase in BALF IL6, which along with IL8 has been touted as a biomarker for acute exacerbations of ILD (AE-ILD) (41,42) (Supplemental Table 2 ). In contrast to IL8, there was no increase in Il6 mRNA expression in Sftpc C121G AT2 cells, suggesting a non-AT2 cell source of IL6 such as the distal lung mesenchyme (43) . In total, Sftpc C121G AT2 cells were an early source of cytokines that mediate the recruitment of multiple immune effector cell populations and are an important contributor to the early lung inflammatory phenotype.
High-dimensional proteomic screen of a pediatric SFTPC BRICHOS mutation cohort translationally overlaps with the Sftpc C121G cytokine profile
The translational relevance of the Sftpc C121G model was assessed in a human pediatric cohort of patients with ChILD. Five patients with ChILD carrying SFTPC BRICHOS mutations and nine control subjects underwent BALF analysis. Subjects with SFTPC BRICHOS mutations had an increase in the total BALF cell count and an increase in the percentage of BALF eosinophils compared to controls (Supplemental Table 3 ). BALF supernatants were analyzed using a SOMAscan aptamer proteomics platform for 1129 proteins, which identified seven proteins increased in the SFTPC BRICHOS subjects'
BALF that met conservative significance criteria (p-value < 0.001; difference greater than 1 on log2 scale).
Five of these proteins were associated with the recruitment of immune cells ( Figure 7A) . Three of these were also increased in the Sftpc C121G model ( Figure 6A ) and have been well described in adult ILD cohorts (44) (45) (46) (47) (48) (49) : CCL2 (MCP-1), CCL17 (TARC) and CCL7 (MCP-3) (Figure 7B-D) . All three of these cytokines are associated with macrophage/monocyte recruitment, the initial effector population identified in the
Cre lungs.
Expression of Sftpc C121G results in the development of spontaneous fibrotic lung remodeling
The lung injury and morbidity observed two weeks post-tamoxifen in the Sftpc C121G/C121G / R26 Quantification of AT2 cells in serial lung sections identified by either proSP-B staining or proSP-C staining at four weeks post-tamoxifen demonstrated a 23.3% ±4.0% (X ± SD, n=3) and 27.5±3.8% (X ± SD, n=3) decline in AT2 cell number from one week post-tamoxifen, respectively, with heterogeneous regions of higher and lower AT2 cell density (Supplemental Figure 8) . Given the concordance in cell number quantified by each AT2 cell specific maker, it appeared that at four weeks after tamoxifen the majority of AT2 cells continue to express Sftpc C121G .
An increase in the potent anti-inflammatory and profibrotic mediator TGF-1 preceded the appearance of the fibrotic remodeling and was commensurate with the resolution of inflammation at two weeks post-tamoxifen ( Figure 8H) . Sftpc C121G AT2 cells were a contributing source of TGF-1, with increases in both gene expression for Tgfb1 ( Figure 8G ) and in AT2 cell TGF-1 staining (Supplemental Figure 9) . Concurrently, MMP-7, a component of the pro-fibrotic milieu, which was elevated in SFTPC BRICHOS patients' BALF (Supplemental Figure 10A ) and has been described in adults with IPF (50), was also increased in the Sftpc C121G/C121G / R26 Cre mice BALF during this transitional period to fibrosis (Supplemental Figure 10B) . Thus, following the resolution of the alveolitis, the Sftpc C121G/C121G / R26 Cre mice express fibrotic mediators and biomarkers found in ChILD and ILD, and develop spontaneous fibrotic lung remodeling with a substantial restrictive impairment in respiratory mechanics.
DISCUSSION
Endoplasmic reticulum stress is a recognized pathway in the pathogenesis of fibrosis in multiple organs, including heart, kidney, liver, and lung (51) . AT2 cell ER stress is also an appreciated feature of the epithelium in sporadic ILD and IPF (17, 52) . There are multiple postulated etiologies for this, including exogenous factors such as air pollution, cigarette smoke exposure (52) , and chronic viral infections (53, 54) .
Additionally, it is hypothesized that epithelial ER stress can arise from dysfunctional epithelial proteostasis in an aging or senescent epithelium (55) (56) (57) . However, in vivo modeling to derive proof of concept linking AT2 cell ER stress and fibrotic lung remodeling has been elusive. Here we present a new model that provides evidence that AT2 expression of a disease-associated SFTPC BRICHOS mutation is sufficient to activate the UPR and produce spontaneous lung inflammation and fibrotic remodeling. Thus, AT2 cell ER stress and our Sftpc C121G model fit within the growing paradigm that disturbance in epithelial cell quality control drives fibrotic lung disease (7, 58) . In support of this, we recently reported on the non-BRICHOS Sftpc I73T mouse model where expression of this trafficking mutation causes defective AT2 cell macroautophagy in the absence of ER stress with resultant spontaneous inflammation and fibrotic lung remodeling (10) . These two models taken together strongly support the notion that distinct endophenotypes of AT2 cell dysfunction may each contribute to ChILD and ILD through both overlapping and distinct pathways.
Previous in vivo SFTPC BRICHOS mutation models have been limited by technical difficulties with the control of relevant gene dosages. Constitutive SFTPC Exon4 mutation expression in mice resulted in dose dependent disrupted lung morphogenesis with prenatal lethality (18) . While that model recapitulated the cell biology of the SFTPC mutation and established a toxic gain of function for SFTPC BRICHOS mutations, the transgenic expression of this highly aggregation prone mutation using a human Based on the importance of the disulfide cysteine bonds in the BRICHOS domain for primary folding and processing (20) and our in vitro modeling of C121 mutant proSP-C isoforms (Figure 1) , we selected an Sftpc mutation that we anticipated would cause significant ER stress. We developed a Figure 2D-F) . However, in the adult inducible model we discovered that heterozygous Sftpc C121G expression was insufficient to develop a robust phenotype. This was similar to what was described in the Sftpc I73T model and likely reflects that either the developing epithelium is more sensitive to the mutated isoforms or that low Sftpc C121G transcription in the heterozygous adult model was inadequate to produce sufficient mutant pro-protein capable of generating a toxic gain of function.
To overcome the limitation of low Sftpc mRNA in the adult inducible model, we selected homozygous Sftpc C121G expression with inducible Cre-driven expression under a strong Rosa26 promoter.
While using this Cre-ERT2 system limited the ability to perform AT2 cell lineage tracing experiments (as could performed with an Sftpc ERT2Cre ), it did produce a gene-dose level closer to predicted levels for heterozygous SFTPC BRICHOS mutation patients, and was capable of inducing a stronge ER stress cellular phenotype. Thus, by modulating gene-dose in both the constitutive and inducible in vivo models, we were able to produce lung phenotypes that recapitulated the spectrum of pediatric and adult SFTPC BRICHOS associated ILD, providing proof of concept linking AT2 cell ER stress and spontaneous fibrotic lung remodeling.
The translational relevance of this model was supported by the discovery of multiple biomarkers associated with human ILD in the Sftpc C121G BALF. These included MMP7, which is a well described marker of fibrotic tissue remodeling in IPF (60) and was identified both in our pediatric proteomic analysis (Supplemental Figure 10 ) and in the Sftpc I73T model. Additionally, we identified IL6 and IL8 in the Sftpc C121G BALF during the inflammatory phase of the model (Supplemental Table 2 ), consistent with analyses of patient samples during AE-ILD that have identified increased plasma levels of IL8 and IL6 as biomarkers associated with worse prognosis (41, 42) .
The role of inflammation and immune effector cell populations in ILD is an area of ongoing research, but the importance of this is highlighted clinically by AE-ILDs. Key cellular features of acute exacerbations include epithelial injury and apoptosis, and the recruitment of a mixed granulocytic cell population (61, 62) . In this regard, the AT2 cell apoptosis (Figure 4F ), alveolitis ( Figure 5F and 5G), and subsequent fibrotic remodeling (Figure 8 ) in our model, recapitulates the human disease. We found that the Sftpc C121G AT2 cell was responsible for early cytokine production associated with immune cell recruitment (Supplemental Figure 7) . This corroborated previous in vitro studies where expression of SFTPC BRICHOS mutations caused the secretion of cytokines associated with immune cell recruitment (13, 14) . The relationship between ER stress and inflammation has been an active area of study in multiple organ systems, including in the pathogenesis of diabetes in the pancreatic B cell (63), hepatic steatosis liver disease (64, 65) , and vascular atherosclerosis (66) . However, that the Sftpc I73T model had both a similar immune cell ontogeny and overlapping AT2 cell produced cytokines suggests that AT2 cell ER stress per se may not underlay the effector cell recruitment (10), but rather that distinct AT2 cell dysfunction endophenotypes converge to produce a common cytokine profile. The regulation of both this immune cell recruitment and then the transition to resolution of alveolitis represent two important areas of future research requiring additional understanding of epithelial-immune cell crosstalk.
Preceding the overt alveolitis, we identified the recruitment of monocyte/macrophage effector cells ( Figure 5I and Figure 6 ). CD11b + Ly6C hi monocytes have been experimentally shown to participate in the development of fibrotic lung disease in exogenous models of injury/repair such as bleomycin and were found to be an early immune population recruited in the Sftpc I73T model (10, 39, 67) . Our models of spontaneous injury suggest that CD11b + Ly6C hi monocytes are recruited to replenish the alveolar macrophage niche, which is consistent with recent evidence showing monocyte-derived alveolar macrophages as a key fibrogenic subset (39) . We found the monocyte/macrophage cytokine CCL2/MCP-1 in the Sftpc C121G BALF, which has previously been identified in fibrotic lung disease and preclinical models (10, 48, 49, (68) (69) (70) . However, we also uncovered elevated levels of CCL17/TARC and CCL7/MCP-3, cytokines with overlapping functional redundancies with CCL2/MCP-1. All three of these cytokines were elaborated in the pediatric proteomic analysis (Figure 7) , proving a translational context to this discovered redundancy, which may account for the phase-two clinical trial failure of pharmacologic MCP-
neutralization as a therapy in IPF (71).
There are multiple possible mechanisms by which fibrosis develops in this model. During the inflammatory phase of the model there is AT2 cell apoptosis, which has been associated with the development of fibrosis in AT2 cell ablation models (72) . However the 20-30% decline in AT2 cell number we observed in this model at four weeks post-tamoxifen was a degree of apoptosis found to be insufficient to induce spontaneous fibrosis in multiple AT2 cell ablation models (73, 74) . Alternatively our data shows that the Sftpc C121G AT2 cell is a source of the potent fibrotic mediator TGF-1 (Figure 8G) , albeit the true contribution of TGF-1 to the development of fibrosis in this model would require TGF-1 depletion. In the lung there has been limited mechanistic work on the link between epithelial ER stress and TGF-1 (57) (75). However, UPR pathways such as ATF4/CHOP have been implicated in TGF-1 production in epithelial injury models of liver and kidney fibrosis (76, 77) . That AT2 cell Tgfb1 expression in the Sftpc C121G model increased two weeks post-tamoxifen demonstrates a temporal sequence of events, with early AT2 cell pro-inflammatory cytokine production followed by a transition to the release of antiinflammatory and pro-fibrotic TGF-1. The regulation of this phenotypic transition may provide additional insights into the accelerated fibrosis that occurs during recovery from an AE-ILD.
In conclusion, the Sftpc C121G model provides a proof of principle for the role of AT2 cell ER stress 
MATERIALS and METHODS
Mouse Models
The Sftpc C121Gneo founder line was commercially produced (Genoway, Inc. Lyon, France) using targeting vector based embryonic stem cell electroporation transfection strategies to knock-in coding sequences for the cysteine-to-glycine substitution at codon 121 into the endogenous mouse Sftpc locus (depicted in Supplemental Figure 1A) . 
Materials and Reagents
Tamoxifen (non-pharmaceutical grade) was purchased from Sigma Aldrich (St Louis, MO).
Cytological slides were stained with Giemsa (#GS500; Sigma Aldrich). All other reagents were electrophoretic or immunological grade and purchased from either Sigma Aldrich or Thermo-Fisher Scientific (Waltham, MA). 
Lung Histology
Immunohistochemistry and Immunofluorescence
Immunohistochemical staining of paraffin-embedded lung sections was performed with primary antibodies at indicated dilutions as described in Supplemental Immunofluorescence staining of lung sections was performed with combinations of primary antibodies and secondary Alexafluor conjugated anti-IgG (Supplemental Table 4 indices were determined by manual counting.
Picrosirius Red Staining
Staining for collagen was performed using the Picosirius Red Stain Kit (Polysciences, Inc., Warrington PA) according to the manufacturer's instructions. Following lung sections staining, five consecutive 20x images were obtained from 2 different lobes (10 peripheral lung fields per section without large airways) for analysis. Digital morphometric measurements were performed using Image J. The mean area of positive picrosirius staining of each lung field was expressed as a percentage of total section area (10, 78) .
Quantification of Lung Collagen Content
Total right lung acid soluble collagen content was determined using the Sircol assay (Biocolor, Ltd; Carrickfergus, UK) according to the manufacturer's instructions and as previously described (69).
Bronchoalveolar Lavage Fluid Collection and Processing
BALF was collected from mice using five sequential 1 ml sterile saline lung lavages. 300L
aliquots of each cell-free, first 1mL of BALF return was removed and stored at -80°C for cytokine analysis.
Cell pellets recovered from centrifugation of complete return were resuspended in 1 ml of sterile saline and total cell counts determined by a Z1 Coulter Counter (Beckman-Coulter, Indianapolis, IN). Differential cell counts were obtained by manually quantifying cytospins of BALF cell pellets stained with modified Giemsa (Sigma Aldrich, #GS500). Large-aggregate surfactant fractions were prepared from cell free BALF by centrifugation at 20,000 X g for 60 min at 4  C as described previously (79) . Total protein content of BALF, surfactant, cell lysate, and whole lung homogenate were assayed by the Bradford method (79) .
Cytokine Analyses
Aliquots of first return, cell free BALF were analyzed for levels of a panel of cytokines (CCL2, CCL11, IL-4, IL-13, IL-5, IL-6, GM-CSF, IL-1, KC(GroA); Panel MCYTOMAG-70K-9) using the Luminex (Luminex Corporation, Austin, TX) multiplex platform analyzed by the Human Immunology
Core at the Perelman School of Medicine. Active TGF-1 and CCL17 (TARC) were measured separately also using Luminex kits (Panel TGFBMAG-64K and MECY2MAG-73K). For select cohorts, CCL7 was measured using a MCP-3 ELISA kit (Cat #BM6006INST, Invitrogen, Waltham, MA).
Mouse Alveolar Type 2 Cell Isolation
Mouse AT2 cells were isolated as previously reported (69) . Briefly, a single cell suspension was 
SDS-PAGE and Immunoblotting
SDS-PAGE using Novex Bis-Tris gels (#NP0301 ThermoFisher Scientific) and immunoblotting of PVDF membranes with primary antibody (Supplemental Table 4 ) was performed. This was followed by species specific horseradish peroxidase conjugated secondary antibody and band detection by enhanced chemiluminescence (ECL2 #80196 ThermoFisher or WesternSure #926-95000, LI-COR Biotechnology, Lincoln, NE) using a LiCor Odyssey Fc Imaging Station and quantized using the manufacturers' software.
Antibodies
A polyclonal proSP-C antiserum ("NPRO-SP-C") raised against rat proSP-C and polyclonal antiproSP-B ("PT3") raised against bovine proSP-B were each produced in rabbits in-house and previously validated as published (80, 81) . The other antibodies used for these studies were obtained from commercial sources (Supplemental Table 4 ).
RNA Isolation and Quantitative Real Time Polymerase Chain Reaction
cDNA was prepared from RNA template purified from AT2 cell or whole lung RNA using the RetroScript Kit. Quantitative single-plex polymerase chain reactions (qRT-PCR) were performed using Taq polymerase and TaqMan RT-PCR kits (Applied Biosystems/ ThermoFisher Scientific) with primer sets for mouse genes listed in Supplemental Table 5 on an ABI Prism 7900 system and a QuantStudio 7 Flex
Real-Time PCR System.
Multichannel Flow Cytometry
Tissue immune cell characterization was performed as previously described (10) . Briefly, En bloc lungs were digested in Dulbecco's Modified Medium (DMEM) + 5% FBS + 2 mg/ml Collagenase D (Cat #11088866001, Roche, Indianapolis, IN), passed through 70-μm nylon mesh to obtain single-cell suspensions, and then mixed with Gibco RBC Lysis Buffer (Cat #A10492-01, Thermo Fisher Scientific).
Cell pellets were resuspended in PBS+0.1% sodium azide and blocked with anti-mouse CD16/32 antibody (Fc block, eBiosciences, San Diego, CA) followed by incubation with antibody mixtures (or isotype controls) and conjugated viability dye (see Supplemental Table 6 ). Single cell suspensions were then analyzed on a LSR Fortessa (BD Biociences, San Jose, CA). They were then gated on viability and singlets and analyzed with FlowJo software (FlowJo, LLC, Ashland, Oregon) based on a modification of the strategy of Misharin, et al (82) as published (10) (Supplemental Figure 6 ).
Pediatric SFTPC Mutation Cohort For Comparative BALF Proteomics
Clinically indicated flexible bronchoscopy was performed and BALF was collected, processed and stored in standard fashion. Disease control subjects were defined as patients with pulmonary symptoms necessitating flexible bronchoscopy including unexplained wheeze, cough, congestion, and recurrent pneumonia, but who had normal-appearing bronchoscopy. BALF cytology and microbiologic testing were performed as part of routine clinical care (83) . Briefly, the area of lavage was picked by the pulmonologist performing the procedure, and in general was performed in areas where mucus had collected, or in area where infiltrate was seen on chest imaging. Typically, three lavages were performed using sterile 
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RFUs were adjusted based on the individual dilution factor for each sample to reflect the initial protein amounts.
Statistical Analysis
For in vitro and in vivo studies all data are presented with dot-plots and group mean ± SEM unless otherwise indicated. Statistical analyses were performed with GraphPad PRISM (SanDiego, CA).
Student's t-test (1 or 2 tailed as appropriate) were used for 2 groups and multiple comparisons were done ANOVA with post hoc testing as indicated; survival analyses was performed using log-rank test. In all cases statistical significance was considered at p-values <0.05.
For the pediatric BALF analysis, adjusted RFUs were log (base 2) transformed and quantile normalization was used to obtain final values for analysis. RFUs for each protein aptamer were compared univariately between groups using difference in log2 means and a two-sample t-test assuming unequal variances. Conservative selection of aptamers included the intersection set with a difference greater than 1 on log2 scale and a p-value < 0.001. This approach provides balance between selecting aptamers with a large absolute change and significant p-value.
Study Approval
Mice were housed in pathogen free facilities according to protocols approved by the IACUC of the Perelman School of Medicine at the University of Pennsylvania. For the pediatric proteomics data, the study was approved by the Colorado Multiple Institutional Review Board (#99-113 and #10-0472).
Informed consent was obtained from all subjects for sample collection and study enrollment. If the patient was a minor, informed consent was obtained from the subject's legal guardian. In subjects aged 12 to 17 years, informed assent was obtained.
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